Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Announcement coincides with WORLDSymposium™ presentation highlighting knockdown of GYS1 mRNA and protein in muscle, as well as favorable safety and ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

Schwartz, MD, of Hattiesburg Clinic Memory Center, urges physicians about Alzheimer’s disease. “Don’t wait,” is the ... or even prevent progression to later stages. There's a robust pipeline of new ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker ... the Tokyo-based company is focused neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi ...